| Drug Type Radiopharmaceuticals and diagnostic agent, Radionuclide Drug Conjugates (RDC) | 
| Synonyms 177Lu-PSMA-3D1015, 3D 1015, 3D1015 | 
| Target | 
| Action inhibitors | 
| Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| PSMA-Positive Castration-Resistant Prostatic Cancer | Clinical | China  | 28 Aug 2025 | |
| Metastatic castration-resistant prostate cancer | Preclinical | China  | 02 Apr 2025 | 





